
Nectar Lifesciences UK Limited

Annual Report and Unaudited Financial Statements

For the year ended 31 March 2020

Company Registration No. 07547409 (England and Wales)

Nectar Lifesciences UK Limited

Company Information

Directors Dr D Dua
Nectar Lifesciences Limited

Company number 07547409

Registered office Devonshire House
60 Goswell Road
London
EC1M 7AD

Accountants Moore Kingston Smith LLP
Betchworth House
57-65 Station Road
Redhill
Surrey
RH1 1DL

Nectar Lifesciences UK Limited

Directors' Report

For the year ended 31 March 2020

The directors present their annual report and financial statements for the year ended 31 March 2020.

Principal activities

The company is dormant and has not traded during the year.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr D Dua
Nectar Lifesciences Limited

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board



Dr D Dua

Director

Date: May 28, 2020

Nectar Lifesciences UK Limited

Balance Sheet

As at 31 March 2020

	Notes	2020 £	£	2019 £	£
Current assets					
Debtors	2	1		1	
Net current assets			<u>1</u>		<u>1</u>
Capital and reserves					
Called up share capital	3		<u>1</u>		<u>1</u>

For the financial year ended 31 March 2020 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved by the board of directors and authorised for issue on
and are signed on its behalf by:


Dr D Dua
Director

Company Registration No. 07547409

Nectar Lifesciences UK Limited

Notes to the Financial Statements

For the year ended 31 March 2020

1 Accounting policies

Company information

Nectar Lifesciences UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is Devonshire House, 60 Goswell Road, London, EC1M 7AD.

1.1 Accounting convention

The financial statements are prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Profit and loss account

The company has not traded during the year or the preceding financial period. During this time the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

1.3 Financial instruments

The company only has financial instruments classified as basic and measured at amortised cost. The company has no financial instruments that are classified as 'other' or financial instruments measured at fair value.

1.4 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2 Debtors

	2020	2019
	£	£
Amounts falling due within one year:		
Amounts due from group undertakings	1	1
	<u>1</u>	<u>1</u>

3 Called up share capital

	2020	2019
	£	£
Ordinary share capital Issued and fully paid		
1 ordinary share of £1	1	1
	<u>1</u>	<u>1</u>

Nectar Lifesciences UK Limited

Notes to the Financial Statements (Continued)

For the year ended 31 March 2020

4 Parent company

The parent company is Nectar Lifesciences Limited, a company registered in India, by virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab, India.

Nectar Lifesciences USA LLC

Directors' Report

For the year ended 31 March 2020

The directors present their annual report and financial statements for the year ended 31 March 2020.

Principal activities

The company has not traded during the year.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

For Nectar Lifesciences USA, LLC



(Sanjiv Goyal)

Operating Manager/ Director

Date: 23-06-2020

Nectar Lifesciences USA LLC

Notes to the Financial Statements for the year ended March 31, 2020

1. Accounting Policies

1.1. Accounting Conventions

The financial statements are prepared under the cost convention and in accordance with the financial reporting standard for smaller entities.

2. Control

The immediate controlling party is Nectar Lifesciences Limited, a company registered in India, by virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt: S.A.S. Nagar (Mohali) Punjab, India.

3. Balance Sheet and Profit and Loss Accounts

Balance Sheet and Profit and Loss Accounts and attached with reports and entries contained there are self explanatory.

4. Audit

Nectar Lifesciences US, LLC, being a privately held company, is not required to get its financial statement audited for the financial year ended on March 31, 2020 under any law of the US.

For Nectar Lifesciences USA, LLC



(Sanjiv Goyal)

Operating Manager/ Director

Date: 23-06-2020

Nectar Lifesciences USA LLC
Balance Sheet As At 31st March 2020

Particulars	NOTE	31-Mar-20 USD	31-Mar-19 USD
<u>EQUITY AND LIABILITIES</u>			
Share holders' Fund			
Share Capital		\$51,950.00	\$51,950.00
Reserves & Surplus	2.1	\$143,146.39	\$73,675.41
Current Liabilities			
Trade Payables	2.2	\$174,976.04	\$1,550,131.04
Total		<u>\$370,072.43</u>	<u>\$1,675,756.45</u>
<u>ASSETS</u>			
Current Assets			
Inventories	2.3	\$320,500.00	\$497,658.00
Trade Receivables	2.4	\$42,305.00	\$1,070,020.00
Cash & Bank Balances	2.5	\$7,267.43	\$108,078.45
		<u>\$370,072.43</u>	<u>\$1,675,756.45</u>

For Nectar Lifesciences USA, LLC

(Sanjiv Goyal)
 Operating Manager/ Director


Date: 23-06-2020

Nectar Lifesciences USA LLC

Statement of Profit and Loss For the Year Ended 31st March 2020

Particulars	NOTE	31-Mar-20 USD	31-Mar-19 USD
INCOME			
Revenue From Operations	2.6	\$3,702,408.61	\$4,273,204.80
		<u>\$3,702,408.61</u>	<u>\$4,273,204.80</u>
EXPENDITURE			
Purchase of Stock in Trade		\$3,341,920.00	\$4,519,750.00
Changes in Inventories of Stock in Trade	2.7	\$177,158.00	(\$497,658.00)
Other Expenses	2.8	\$113,859.63	\$164,925.20
		<u>\$3,632,937.63</u>	<u>\$4,187,017.20</u>
PROFIT BEFORE TAX		\$69,470.98	\$86,187.60

For Nectar Lifesciences USA, LLC



(Sanjiv Goyal)
Operating Manager/ Director

Date: 23-06-2020

Nectar Lifesciences USA LLC

Particulars	31-Mar-20 USD	31-Mar-19 USD
NOTE - 2.1 "RESERVES & SURPLUS"		
Surplus in Statement of Profit & Loss		
Opening Balance:	\$73,675.41	(\$12,512.19)
Transferred From Statement of Profit & Loss	<u>\$69,470.98</u>	<u>\$86,187.60</u>
	\$143,146.39	\$73,675.41
Appropriations :		
Corporation Business Tax	\$0.00	\$0.00
Total	<u>\$143,146.39</u>	<u>\$73,675.41</u>
 NOTE - 2.2 "TRADE PAYABLES"		
Trade Payables	<u>\$174,976.04</u>	<u>\$1,550,131.04</u>
	<u>\$174,976.04</u>	<u>\$1,550,131.04</u>

For Nectar Lifesciences USA, LLC


(Sanjiv Goyal)
Operating Manager/ Director

Date: 23-06-2020


Nectar Lifesciences USA LLC

Particulars	31-Mar-20 USD	31-Mar-19 USD
NOTE - 2.3 "INVENTORIES"		
(As Certified by The Management)		
Finished Goods	\$320,500.00	\$497,658.00
	<u>\$320,500.00</u>	<u>\$497,658.00</u>

NOTE - 2.4 "TRADE RECEIVABLES"		
Unsecured		
Considered Good	\$42,305.00	\$1,070,020.00
Considered Doubtful	-	-
	<u>\$42,305.00</u>	<u>\$1,070,020.00</u>
Provision For Doubtful Debts	-	-
	<u>\$42,305.00</u>	<u>\$1,070,020.00</u>

NOTE - 2.5 "CASH & BANK BALANCES"		
Balance With Banks		
In Current Accounts	\$7,267.43	\$108,078.45
	<u>\$7,267.43</u>	<u>\$108,078.45</u>

For Nectar Lifesciences USA, LLC



 (Sanjiv Goyal)
 Operating Manager/ Director

Date: 23-06-2020

Nectar Lifesciences USA LLC

Particulars	31-Mar-20 USD	31-Mar-19 USD
NOTE - 2.6 "REVENUE FROM OPERATIONS"		
Sale from Operations	\$3,702,408.61	\$4,273,204.80
	\$3,702,408.61	\$4,273,204.80
 NOTE - 2.7 "CHANGE IN STOCK IN TRADE"		
Inventory (At Close)	\$320,500.00	\$497,658.00
Inventory (At Commencement)	\$497,658.00	\$0.00
Change	\$177,158.00	(\$497,658.00)
 NOTE - 2.8 "OTHER EXPENSES"		
Administrative & Selling Expenses		
Freight Charges	\$85,022.63	\$146,136.20
Professional Charges	\$28,484.00	\$6,525.00
Provision for Bad Debts/ Bad Debts Written off	-	\$12,000.00
Bank Charges & Commission	\$353.00	\$264.00
	\$113,859.63	\$164,925.20

For Nectar Lifesciences USA, LLC


 (Sanjiv Goyal)
 Operating Manager/ Director

Date: 23-06-2020

Neclife PT, Unipessoal LDA – Portugal

Directors' Report
For the year ended 31 March 2020

The directors present their annual report and financial statements for the year ended 31 March 2020.

Principal activities

The company has not traded during the year.

Directors


The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr Dinesh Dua
Nectar Lifesciences Limited

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

For **Neclife PT, Unipessoal LDA**

Date: 23-06-2020


(Dr. Dinesh Dua)
Manager/ Director

**Neclife PT, Unipessoal LDA – Portugal
Balance Sheet as at March 31, 2020**

Assets	Note	31.03.20
Cash & Cash Equivalents Cash & Bank Balances	3	€ 1,000
Total		€ 1,000
Liabilities		
Shareholder's Fund Share Capital	4	€ 1,000
Total		€ 1,000

Cash & Cash Equivalents **Note - 3**


Particulars	31.03.20
Cash & Bank Balance	€ 1,000
Total	€ 1,000

Share Capital **Note - 4**

Particulars	31.03.20
Issued and paid up share capital	€ 1,000
Total	€ 1,000

For Neclife PT, Unipessoal LDA

Date: 23-06-2020


(Dr. Dinesh Dha)
Manager/ Director

Neclife PT, Unipessoal LDA – Portugal

Notes to Financial Statements For the year ended March 31, 2020

1. Accounting Policies

1.1 Accounting Conventions

The financial statements are prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The financial statements are prepared in Euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest euro.

1.2 Profit & Loss Account

The company has not traded during the year. During this time the company received no income and incurred no expenditure and therefore no profit & loss account is presented in these financial statements.

1.3 Equity Instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable (if any) on equity instruments are recognized as liabilities once they are no longer at the discretion of the company.

2. Parent Company

The parent company is Nectar Lifesciences Limited, a company registered in India, by the virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.


Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Disst. S.A.S. Nagar (Mohali), Punjab, India.

3. Audit

Neclife PT, Unipessoal LDA, being a privately held company, is not required to get its financial statement audited for the financial year ended on March 31, 2020 under any law of the US.

For Neclife PT, Unipessoal LDA

Date: 23-06-2020


(Dr. Dinesh Dua)
Manager/ Director